Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6069214 | 0.84 | PTGS1 (0.61) | KDM4ESMN1; SMN2CTBP2MAPTKMT2A | |
| SCHEMBL6069208 | 0.84 | PTGS1 (0.61) | KDM4ESMN1; SMN2CTBP2MAPTKMT2A | |
| SCHEMBL25890179 | 0.82 | KDM4E (0.51) | KDM4ESMN1; SMN2CTBP2HTTALDH1A1 | |
| SCHEMBL873860 | 0.80 | ACACB (0.43) | KDM4ESMN1; SMN2CTBP2ALDH1A1MAPT | |
| SCHEMBL3665017 | 0.79 | HTT (0.59) | KDM4ESMN1; SMN2CTBP2HTTALDH1A1 | |
| SCHEMBL101734 | 0.78 | ALDH1A1 (0.63) | KDM4ESMN1; SMN2CTBP2HTTALDH1A1 | |
| SCHEMBL101733 | 0.78 | ALDH1A1 (0.63) | KDM4ESMN1; SMN2CTBP2HTTALDH1A1 | |
| SCHEMBL3531472 | 0.78 | ALDH1A1 (0.63) | KDM4ESMN1; SMN2CTBP2HTTALDH1A1 | |
| SCHEMBL13268901 | 0.77 | SMN1; SMN2 (0.59) | KDM4ESMN1; SMN2CTBP2HTTALDH1A1 | |
| SCHEMBL9564540 | 0.77 | SMN1; SMN2 (1.00) | KDM4ESMN1; SMN2CTBP2HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | SENDA BIOSCIENCES INC (US) | 2023-07-27 | — | — | US | disclosed |
| CN-104382924-A | N6-substituted adenosine derivative and N6-substituted adenine derivative and application thereof | INST MATERIA MEDICA CAMS | 2015-03-04 | — | — | CN | disclosed |
| EP-2227475-A1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | Fibrogen, Inc. (US) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009073669-A1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | FIBROGEN, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
| US-4880840-A | ANIMAL GROWTH REGULATORS | BAYER AKTIENGESELLSCHAFT (DE) | 1989-11-14 | — | — | US | disclosed |
| EP-0253258-A2 | Arylethanolhydroxylamines, method for their production and their application as performance promoters | BAYER AG (DE) | 1988-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | ASNS, SI, NARS1 | KDM4E 4207/4885SMN1; SMN2 1784/4885CTBP2 4724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.